Date | Title | Description | |
---|---|---|---|
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
21 Feb 2023 | On business and financial situation | The company releases the Integrated Report for the year 2022 | Download |
21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted on 3 and 4 November | Download |
03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Nov 2012 | Composición Consejo de Administración | Download | |
18 Sep 2012 | Otros sobre negocio y situación financiera | Download | |
26 Jul 2012 | Información sobre resultados (2) | Download | |
26 Jul 2012 | Información sobre resultados | Download | |
26 Jul 2012 | Información financiera intermedia | Download |